Partner agreement with SymbioPharm

About this update from Probiotix Health Plc

ProBiotix H eal th p l c ( "ProBiotix" or the "Company")   Partner agreement with SymbioPharm   ProB i ot i x H ealth p l c (A QUIS : PBX), a li f e sc i ences bu s i n ess d e ve l o p i n g probiotics to support cardiometabolic health , announces it has entered into a partnership agreement with SymbioPharm, a German company pioneering in microbiome research and knowledge-based probiotics. SymbioPharm has secured its position as a leading innovator and provider of probiotics, medicinal products and dietary supplements in Germany, Austria and Switzerland where it is considered a top tier consumer brand. SymbioPharm's distribution network spans direct-to-consumer channels as well as a comprehensive online and offline pharmacy presence.   The agreement allows SymbioPharm to utilise ProBiotix's CholBiome ® CH formulation to target and reduce cholesterol in their branded consumer products. SymbioPharm has introduced the CholBiome® CH formulation as a premium pharmacy supplement solution across targeted regions. The agreement covers sales in Germany, Austria and Switzerland, focusing on maximising market penetration through strategic pharmacy partnerships.   The unique and innovative formulation developed by ProBiotix comes with a European Food Safety Authority (EFSA) health claim, specific for cholesterol.   Steen Andersen, CEO of ProBiotix Health plc commented: " We are delighted that Symbiopharm, a recognised leader in the probiotic space, has engaged with ProBiotix Health. This collaboration is strategically aligned with our goal of extending the reach of our unique finished product formulations within the DACH region (Germany, Austria and Switzerland). This is an important step for us to further expand our business in the consumer health segment, and allow us to reach a broader audience, enhancing market presence and influence."   Tobias Brodtkorb, CEO of SymbioPharm added: "We are very pleased to have entered into this agreement with ProBiotix Health. We are a collaborative business and are passionate about natural treatments using live bacteria. Our focus is not only on effective therapies, but also on the associated diagnostics and scientific research on the  microbiome, and we find our model fits in naturally with ProBiotix and their mission. We are delighted to be working closely with them and hope for a strong relationship going forward."   For further information, please contact:   ProBiotix Health plc https://probiotixhealth-ir.com/ Steen Andersen, Chief Executive Contact via Walbrook below Peterhouse Capital Limited ( Aquis Corporate Adviser and Broker) Tel: 020 7469 0930 Mark Anwyl Duncan Vasey   Walbrook PR Ltd [email protected] Anna Dunphy Mob: 07876 741 001    

View stock analysis, news, and events for Probiotix Health Plc